•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
IXICO PLC (LSE:IXI, OTC:PHYOF, FRA:PYPB) CEO Bram Goorden said the company’s first-half performance reflected a continuation of a trend reversal seen in 2025, with revenue growth and a rising order book indicating increasing momentum in its core clinical trials analytics business.
Goorden said the headline figure for the period was a 23% increase in revenue. He attributed the growth primarily to more contracts and contract extensions, alongside increased volume and analytics usage.
He described IXICO as having previously operated at a subscale, while having a platform that is now “ready for more scale.” He pointed to rising volumes and analytics capacity, including a record high of revenue in March linked to analytics as volumes increased.
Goorden said IXICO is focusing on clinical trials in Alzheimer’s, Parkinson’s, and the broader rare CNS space. He also noted further validation of blood-based biomarker products and a move toward later-stage clinical trials, including phase two and phase three.
He referenced a phase three trial win announced at the end of last year and a phase two extension more recently.
Looking ahead over the next six months, Goorden said the company’s focus would be “more of the same,” emphasizing scaling up to improve margins and profitability.
He reported that IXICO’s margin reached 53%, which he said was 4 percentage points higher than in the same period last year. On profitability, he said EBITDA was just shy of negative £0.5 million for the half, adding that the company is getting closer to profitability.
Goorden also highlighted the order book, stating it is at a record high since several years of £18.1 million, representing a 38% increase. He said filling the order book is central to driving scale and further profitability through the remainder of the year.
Goorden said IXICO’s recent fundraising is intended to support a new TechBio strategy and unlock additional revenue drivers. He said the company announced a £10 million raise, describing it as significant for the company’s size and noting support from both existing and new shareholders.
He said the strategy is to broaden platform use beyond IXICO’s own experts by partnering with other players in the clinical trial space. He described the goal as generating recurring revenue through licensing and partnerships, which would require standardizing and automating the platform to integrate with partners.
Goorden said the company has already signed a partnership intended to “bring this to life,” citing a collaboration with Medidata. He described Medidata as the largest electronic data capturing provider in clinical trials, serving 18 of the 25 big pharma clients, and supporting 80% of all clinical research organizations.
He said Medidata’s reach and impact, combined with IXICO’s precision analytics technology, is intended to demonstrate how the platform can be partnered and scaled.
Goorden said IXICO will continue to deliver on its core business momentum while implementing the TechBio strategy. He noted the company had promised at least 15% growth and said the 23% first-half result exceeded that target, adding that the fundraising will enable the next phase of platform partnerships.
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
